InMed Pharmaceuticals Inc. Common Shares (INM)
Stock · NASDAQ · Health Care
$1.32as of 10/16/2026
Price chart
Active signals
INM Signal Track Record
How signals performed across all stocks →What INM's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | -12.1% | 24% | September 17, 2026 |
| Bollinger Band Breakdown | 24 | -5.9% | 42% | May 8, 2026 |
| Bollinger Band Breakout | 20 | -14.4% | 10% | October 9, 2026 |
| 200-Day Moving Average TouchActive now | 3 | -21.9% | 0% | June 25, 2025 |
| Any 20-session window (baseline) | -10.1% | 29% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About INM
InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States. The company researches and develops cannabinoid-based pharmaceuticals products. Its product candidates include INM-901 for Alzheimer's disease, INM-089 for dry age-related macular degeneration, and INM-755, a cannabinol cream. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 6
- Website
- www.inmedpharma.com/
Fundamentals
- 1-day range
- $1.31$1.34
- Market cap
- $4.01M
- P/E (trailing)
- —
- P/E (forward)
- -0.21
- EPS (trailing)
- $-2.88
- Dividend yield
- —
- Beta
- 1.05
- Avg. volume
- 928.5K
- Dividend pay date
- July 6, 2020
How InMed Pharmaceuticals Inc. Common Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Sep 23, 2025 · via SEC EDGAR / Finnhub
InMed Pharmaceuticals Inc. Common Shares Competitors
Chosen by industry and closest market cap.
- INMInMed Pharmaceuticals Inc. Common Shares$1.32▼ 0.75%Market cap $4.01MP/E —$0.575$2.33
- MBIOMustang Bio Inc. Common Stock$0.376▼ 2.59%Market cap $3.87MP/E —$0.3701$1.69
- SPRCSciSparc Ltd. Ordinary Shares$1.7▼ 15.00%Market cap $3.85MP/E —$1.63$43.65
- JUNSJupiter Neurosciences Inc. Common Stock$2.9▼ 7.48%Market cap $4.24MP/E —$2.25$135.75
- ELABPMGC Holdings Inc. Common Stock$2.77▼ 8.88%Market cap $4.34MP/E —$2.59$2,671
- REVBRevelation Biosciences Inc. Common Stock$0.485▼ 36.35%Market cap $4.38MP/E 0.04$0.71$5.8
- DRMADermata Therapeutics Inc. Common Stock$0.86▼ 5.49%Market cap $4.46MP/E —$0.6032$4.66
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| INM InMed Pharmaceuticals Inc. Common Shares | $4.01M | — | $1.32 | ▼ 0.75% | $0.575$2.33 |
| MBIO Mustang Bio Inc. Common Stock | $3.87M | — | $0.376 | ▼ 2.59% | $0.3701$1.69 |
| SPRC SciSparc Ltd. Ordinary Shares | $3.85M | — | $1.7 | ▼ 15.00% | $1.63$43.65 |
| JUNS Jupiter Neurosciences Inc. Common Stock | $4.24M | — | $2.9 | ▼ 7.48% | $2.25$135.75 |
| ELAB PMGC Holdings Inc. Common Stock | $4.34M | — | $2.77 | ▼ 8.88% | $2.59$2,671 |
| REVB Revelation Biosciences Inc. Common Stock | $4.38M | 0.04 | $0.485 | ▼ 36.35% | $0.71$5.8 |
| DRMA Dermata Therapeutics Inc. Common Stock | $4.46M | — | $0.86 | ▼ 5.49% | $0.6032$4.66 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- ADAR1 Capital Management, LLC · October 8, 2026 · Buy2.3K @ $1.33
- ADAR1 Capital Management, LLC · October 7, 2026 · Buy3.0K @ $1.33
- ADAR1 Capital Management, LLC · October 6, 2026 · Buy5.6K @ $1.33
- ADAR1 Capital Management, LLC · October 5, 2026 · Buy18.2K @ $1.33
- ADAR1 Capital Management, LLC · October 2, 2026 · Buy8.3K @ $1.33
- ADAR1 Capital Management, LLC · October 1, 2026 · Buy16.4K @ $1.33
- ADAR1 Capital Management, LLC · September 16, 2026 · Buy8.3K @ $1.29
- ADAR1 Capital Management, LLC · September 15, 2026 · Buy54.3K @ $1.3
- ADAR1 Capital Management, LLC · September 14, 2026 · Buy28.5K @ $1.29
- Vivo Opportunity, LLC · July 16, 2026 · Buy2 @ $1.55
- Vivo Opportunity, LLC · July 16, 2026 · Buy19 @ $1.55
- ADAR1 Capital Management, LLC · July 15, 2026 · Buy1.0K @ $1.56
- Vivo Opportunity, LLC · July 15, 2026 · Buy1.4K @ $1.55
- Vivo Opportunity, LLC · July 15, 2026 · Buy13.8K @ $1.55
- Vivo Opportunity, LLC · July 14, 2026 · Buy493 @ $1.55
Institutional Ownership
March 31, 2026
- Total shares held
- 319.3K
- Total value held
- $193.0K
- Institutional holders
- 9
- Unknown220.3K
- Unknown47.0K
- Unknown20.0K
- Unknown18.7K
- Unknown8.1K
- Unknown5.0K
- Unknown300
- Unknown6
- Unknown2
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
INM: No recent news reported
There were no new announcements or events involving InMed Pharmaceuticals in the past week. The only article listed concerns Liquidia, which does not affect INM directly. Therefore, no new information is available to influence the company's outlook at this time.
INM: No recent news reported. There were no new announcements or events involving InMed Pharmaceuticals in the past week. The only article listed concerns Liquidia, which does not affect INM directly. Therefore, no new information is available to influence the company's outlook at this time.